| Literature DB >> 35725251 |
Agazhe Aemro1, Belayneh Shetie Workneh2, Enyew Getaneh Mekonen3, Mulugeta Wassie4, Basazinew Chekol5.
Abstract
OBJECTIVE: The aim of this study was to assess the prevalence of anaemia and its associated factors at the time of antiretroviral therapy (ART) initiation among HIV-infected adults at Debre Markos Comprehensive Specialized Hospital.Entities:
Keywords: haematology; immunology; infectious diseases
Mesh:
Year: 2022 PMID: 35725251 PMCID: PMC9214405 DOI: 10.1136/bmjopen-2021-057235
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 3.006
Prevalence of anaemia at the time of ART initiation stratified by sociodemographic characteristics of HIV-infected adults at Debre Markos Comprehensive Specialized Hospital from 1 January 2014 to 31 December 2018 (n=468)
| Characteristics | Frequency (%) | Anaemia status | P value | |
| Anaemic (%) | Not anaemic (%) | |||
| Sex | ||||
| Male | 187 (39.96) | 86 (45.99) | 101 (54.01) | <0.001 |
| Female | 281 (60.04) | 77 (27.40) | 204 (72.60) | |
| Age in years | ||||
| 15–24 | 51 (10.90) | 11 (21.57) | 40 (78.43) | 0.138 |
| 25–34 | 190 (40.60) | 65 (34.21) | 125 (65.79) | |
| 35–44 | 157 (33.55) | 61 (38.85) | 96 (61.15) | |
| ≥45 | 70 (14.96) | 27 (38.57) | 43 (61.43) | |
| Religion | ||||
| Orthodox | 447 (95.51) | 158 (35.35) | 289 (64.65) | 0.677 |
| Muslim | 20 (4.27) | 6 (30.00) | 14 (70.00) | |
| Protestant | 1 (0.21) | 0 | 1 (100.00) | |
| Marital status | ||||
| Single | 56 (11.97) | 18 (32.14) | 38 (67.86) | 0.813 |
| Married | 251 (53.63) | 85 (33.86) | 166 (66.14) | |
| Divorced/separated | 125 (26.71) | 47 (37.60) | 78 (62.40) | |
| Widowed | 36 (7.69) | 14 (38.89) | 22 (61.11) | |
| Educational level | ||||
| No education | 171 (36.54) | 62 (36.26) | 109 (63.74) | 0.365 |
| Primary | 109 (23.29) | 38 (34.86) | 71 (65.14) | |
| Secondary | 113 (24.15) | 44 (38.94) | 69 (61.06) | |
| College+ | 75 (16.03) | 20 (26.67) | 55 (73.33) | |
| Residence | ||||
| Rural | 101 (21.58) | 45 (44.54) | 56 (55.45) | 0.024 |
| Urban | 367 (78.42) | 119 (32.43) | 248 (67.57) | |
| Occupation | ||||
| Employed | 153 (32.69) | 50 (32.68) | 103 (67.32) | 0.455 |
| Unemployed | 315 (67.31) | 114 (36.19) | 201 (63.81) | |
| Family size | ||||
| <2 persons | 187 (39.96) | 55 (29.41) | 132 (70.59) | 0.112 |
| 3–4 persons | 213 (45.51) | 82 (38.50) | 131 (61.50) | |
| >4 persons | 68 (14.53) | 27 (39.71) | 41 (60.29) | |
| HIV disclosure status | ||||
| Disclosed | 426 (91.03) | 149 (34.98) | 277 (65.02) | 0.924 |
| Not disclosed | 42 (8.97) | 15 (35.71) | 27 (64.29) | |
ART, antiretroviral therapy.
Prevalence of anaemia at the time of ART initiation stratified by clinical and immunological-related characteristics of HIV-infected adults at Debre Markos Comprehensive Specialized Hospital from 1 January 2014 to 31 December 2018 (n=468)
| Characteristics | Frequency (%) | Anaemia status | P value | |
| Anaemic (%) | Not anaemic (%) | |||
| Pre-ART duration | ||||
| <6 months | 332 (70.94) | 122 (36.75) | 210 (63.25) | 0.227 |
| ≥6 months | 136 (29.06) | 42 (30.88) | 94 (69.12) | |
| Past OI | ||||
| Yes | 78 (16.67) | 34 (43.59) | 44 (56.41) | 0.083 |
| No | 390 (83.33) | 130 (33.33) | 260 (66.67) | |
| Past CPT treatment | ||||
| Yes | 93 (19.87) | 32 (34.41) | 61 (65.59) | 0.886 |
| No | 375 (80.13) | 132 (35.02) | 243 (64.80) | |
| Past INH prophylaxis | ||||
| Yes | 15 (3.21) | 3 (20.00) | 12 (80.00) | 0.215 |
| No | 453 (96.79) | 161 (35.54) | 292 (64.46) | |
| Past TB treatment history | ||||
| Yes | 14 (2.99) | 8 (57.14) | 6 (42.86) | 0.078 |
| No | 454 (97.01) | 156 (34.36) | 298 (65.64) | |
| Baseline WHO clinical staging | ||||
| I | 197 (42.09) | 43 (21.83) | 154 (78.17) | <0.001 |
| II | 121 (25.85) | 35 (28.93) | 86 (71.07) | |
| III | 121 (25.85) | 63 (52.07) | 58 (47.93) | |
| IV | 29 (6.20) | 23 (79.31) | 6 (20.69) | |
| Baseline CD4 count (cells/μL) | ||||
| <100 | 89 (19.02) | 62 (69.66) | 27 (30.34) | <0.001 |
| 100–199 | 74 (15.81) | 41 (55.41) | 33 (44.59) | |
| 200–349 | 124 (26.50) | 34 (27.42) | 90 (72.58) | |
| ≥350 | 181 (38.68) | 27 (14.92) | 154 (85.08) | |
| Baseline BMI | ||||
| <18.5 | 134 (28.63) | 78 (58.21) | 56 (41.79) | <0.001 |
| 18.5–24.9 | 286 (61.11) | 76 (26.57) | 210 (73.43) | |
| >24.9 | 48 (10.26) | 10 (20.83) | 38 (79.17) | |
| Baseline functional status | ||||
| Working | 370 (79.06) | 93 (25.14) | 277 (74.86) | <0.001 |
| Ambulatory | 90 (19.23) | 65 (72.22) | 25 (27.78) | |
| Bedridden | 8 (1.71) | 6 (75.00) | 2 (25.00) | |
ART, antiretroviral therapy; BMI, body mass index; CPT, cotrimoxazole preventive therapy; INH, isoniazid; OI, opportunistic infection; TB, tuberculosis.
Figure 1Level of anaemia at the time of ART initiation among HIV-infected adults at Debre Markos Comprehensive Specialized Hospital. ART, antiretroviral therapy.
Bivariate and multivariable logistic regression analyses of factors associated with anaemia at the time of ART initiation among HIV infected adults at Debre Markos Comprehensive Specialized Hospital from 1 January 2014 to 31 December 2018 (n=468)
| Characteristics | Frequency | COR (95% CI) | AOR (95% CI) | P value | |
| Anaemic | Not anaemic | ||||
| Sex of the patient | |||||
| Male | 86 | 101 | 2.30 (1.56 to 3.40) | 2.45 (1.51 to 3.98) |
|
| Female | 77 | 204 | 1.00 | 1.00 | |
| Age at enrolment (in years) | |||||
| 15–24 | 11 | 40 | 1.00 | 1.00 | |
| 25–34 | 65 | 125 | 1.89 (0.91 to 3.93) | 1.96 (0.79 to 4.85) | 0.145 |
| 35–44 | 60 | 97 | 2.31 (1.10 to 4.85) | 1.65 (0.65 to 4.22) | 0.295 |
| 45+ | 27 | 43 | 2.28 (1.003 to 5.19) | 1.65 (0.58 to 4.67) | 0.346 |
| Level of education | |||||
| No education | 62 | 109 | 1.57 (0.88 to 2.82) | 2.38 (1.12 to 5.05) |
|
| Primary | 37 | 72 | 1.32 (0.70 to 2.51) | 1.69 (0.76 to 3.77) | 0.195 |
| Secondary | 44 | 69 | 1.87 (1.01 to 3.45) | 1.88 (0.87 to 4.04) | 0.107 |
| College+ | 20 | 55 | 1.00 | 1.00 | |
| Patient’s residence | |||||
| Rural | 118 | 249 | 1.67 (1.07 to 2.62) | 1.58 (0.91 to 2.75) | 0.105 |
| Urban | 45 | 56 | 1.00 | 1.00 | |
| Family size | |||||
| ≤2 persons | 55 | 132 | 1.00 | 1.00 | |
| 3–4 persons | 81 | 132 | 1.50 (0.99 to 2.28) | 1.30 (0.76 to 2.22) | 0.333 |
| ≥5 persons | 27 | 41 | 1.58 (0.89 to 2.82) | 1.41 (0.68 to 2.94) | 0.352 |
| Pre-ART duration | |||||
| <6 months | 122 | 210 | 1.00 | 1.00 | |
| ≥6 months | 42 | 94 | 0.77 (0.50 to 1.17) | 0.93 (0.55 to 1.60) | 0.807 |
| Presence of past OI | |||||
| Yes | 34 | 44 | 1.55 (0.94 to 2.53) | 0.88 (0.46 to 1.69) | 0.708 |
| No | 130 | 260 | |||
| CD4+ T cell count at enrolment (cells/μL) | |||||
| <200 | 103 | 60 | 6.86 (4.49 to 10.49) | 4.67 (2.78 to 7.85) |
|
| ≥200 | 61 | 244 | 1.00 | 1.00 | |
| Body mass index (kg/m2) | |||||
| <18.5 | 78 | 56 | 3.85 (2.49 to 5.93) | 2.43 (1.42 to 4.16) |
|
| 18.5–24.9 | 76 | 210 | 1.00 | 1.00 | |
| >24.9 | 10 | 38 | 0.73 (0.35 to 1.53) | 1.26 (0.54 to 2.93) | 0.593 |
| WHO clinical staging | |||||
| Stage I | 43 | 158 | 1.00 | 1.00 | |
| Stage II | 35 | 86 | 1.49 (0.89 to 2.51) | 0.94 (0.51 to 1.73) | 0.850 |
| Stage III/IV | 86 | 60 | 5.27 (3.29 to 8.44) | 1.78 (0.96 to 3.30) | 0.068 |
| Functional status at enrolment | |||||
| Working | 93 | 277 | 1.00 | 1.00 | |
| Ambulatory/bedridden | 71 | 27 | 7.83 (4.74 to 12.93) | 2.69 (1.41 to 5.12) |
|
*Significance at a p value of <0.05.
AOR, adjusted OR; ART, antiretroviral therapy; COR, crude OR; OI, opportunistic infection.